Leaflet: information for the user
Vardenafilo STADA 5 mg film-coated tablets
Vardenafilo STADA 10 mg film-coated tablets
Vardenafilo STADA 20 mg film-coated tablets
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
-Keep this leaflet, as you may need to read it again.
-If you have any questions, ask your doctor or pharmacist.
-This medicine has been prescribed for you only. Do not give it to others even if they have the same symptoms as you, as it may harm them.
-If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. See section 4.
1.What Vardenafilo Stada is and what it is used for
2.What you need to know before you start taking Vardenafilo Stada
3.How to take Vardenafilo Stada
4.Possible side effects
5.Storage of Vardenafilo Stada
6.Contents of the pack and additional information
Vardenafilo Stada contains vardenafilo, an active ingredient from the group of medications known as phosphodiesterase type 5 inhibitors, which are used to treat erectile dysfunction in adult men, a condition that consists of difficulty in achieving or maintaining an erection.
At least one in every ten men has, at some point, problems achieving or maintaining an erection. This may be due to physical or psychological causes, or a combination of both. Regardless of the cause, muscle and blood vessel alterations result in insufficient blood in the penis to achieve and maintain an erection.
Vardenafilo will only act when sexually stimulated. This medication reduces the action of a natural substance in the body that prevents an erection. Vardenafilo allows for the achievement of an erection with a sufficient duration to maintain a satisfactory sexual relationship.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Vardenafilo Stada.
Be especially careful with Vardenafilo Stada
Children and adolescents
Vardenafilo should not be used in children or adolescents under 18 years old.
Other medications and Vardenafilo Stada
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication, including those purchased without a prescription.
Some medications may cause problems, especially the following:
Do not use vardenafilo tablets coated with a film in combination with another medication for erectile dysfunction, including vardenafilo buccal dispersible tablets.
Taking Vardenafilo Stada with food, drinks, and alcohol
Pregnancy and breastfeeding
Vardenafilo should not be used in women.
Driving and operating machinery
In some people, vardenafilo may cause dizziness or affect vision. Do not drive or operate tools or machinery if you feel dizzy or have vision problems after taking vardenafilo.
This medication contains sodium
This medication contains less than 23 mg of sodium (1 mmol) per tablet; it is essentially “sodium-free”.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
The recommended dose is 10 mg.
Take a vardenafilo tablet25 to 60 minutes, approximately, before sexual activity. With sexual stimulation, you will be able to obtain an erection from 25 minutes and up to four or five hours after taking vardenafilo.
Swallow the tablet with a glass of water.
Do not take vardenafilofilm-coated tabletswith any other formulation of vardenafilo.
Do not take vardenafilomore than once a day.
If you estimate that the action of vardenafilois too strong or weak, inform your doctor. They may suggest changing to another formulation of vardenafilowith a different dose based on the effect it has on you.
If you take more Vardenafilo Stada than you should
Taking too many vardenafilo tabletsmay cause more side effects and produce intense back pain. In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service at telephone 91 562 04 20, indicating the medication and the amount ingested.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them. Most of these side effects are mild or moderate.
Some patients have experienced a decrease in vision or partial loss of vision, sudden, temporary, or permanent, in one or both eyes. Stop taking vardenafil and contact your doctor immediately.
There have also been reported cases of sudden hearing loss or hearing loss.
There have been reported cases of sudden death, rapid or irregular heartbeats, heart attacks, chest pain, and cerebral circulation problems (including temporary reduction of blood flow to parts of the brain and cerebral hemorrhage), in men taking vardenafil. Most men who have experienced these side effects had pre-existing heart problems before taking this medicine. It is not possible to determine if these events were directly related to vardenafil.
The possibility of presenting a side effect is described using the following categories:
Very common side effects (can affect more than 1 in 10 people):
Common side effects (can affect up to 1 in 10 people):
Uncommon side effects (can affect up to 1 in 100 people):
Rare side effects (can affect up to 1 in 1,000 people):
Very rare or unknown frequency side effects (can affect fewer than 1 in 10,000 people or the frequency cannot be estimated from available data):
Reporting of side effects
If you experience any type of side effect, consult your doctor, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not store at a temperature above 30°C.
Do not use this medication after the expiration date that appears on the packaging and blister after “CAD”. The expiration date is the last day of the month indicated.
Medicines should not be disposed of through drains or in the trash. Dispose of the containers and medicines you no longer need at the SIGRE collection point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. By doing so, you will help protect the environment.
Composition of Vardenafilo Stada
-The active ingredient is vardenafilo.
Vardenafilo Stada 5 mg: each tablet contains 5 mg of vardenafilo (as trihydrate hydrochloride).
Vardenafilo Stada 10 mg: each tablet contains 10 mg of vardenafilo (as trihydrate hydrochloride).
Vardenafilo Stada 20 mg: each tablet contains 20 mg of vardenafilo (as trihydrate hydrochloride).
-The other components are:
Tablet core: microcrystalline cellulose (E460); crospovidone type A (E1202); anhydrous colloidal silica (E551); magnesium stearate (E470b).
Coating:polyvinyl alcohol (E1203); titanium dioxide (E171); talc (E553b); macrogol (E1521); acid methacrylic copolymer; yellow iron oxide (E172); sodium hydrogen carbonate (E500 (ii)); red iron oxide (E172).
Appearance of the product and contents of the package
Vardenafilo Stada 5 mg are round tablets, coated with a yellowish clear film of 6 mm and engraved with “A719” on one side.
Vardenafilo Stada 10 mg are round tablets, coated with a yellowish clear film of 7 mm and engraved with “A721” on one side.
Vardenafilo Stada 20 mg are round tablets, coated with a yellowish clear film of 8.5 mm and engraved with “A723” on one side.
It is presented in PVC/Aclar-Al blisters containing:
Vardenafilo Stada 5 mg: 4, 12 or 20 tablets.
Vardenafilo Stada 10 mg and Vardenafilo Stada 20 mg: 2, 4, 8, 12 or 20 tablets.
Only some package sizes may be marketed.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder
STADA, S.L.
Frederic Mompou, 5
08960 Sant Just Desvern (Barcelona)
Spain
Responsible manufacturer
STADA Arzneimittel AG
Stadastasse 2-18
61118 Bad Vilbel
Germany
or
Actavis Ltd.
BLB016, Bulebel Industrial Estate
Zejtun ZTN 3000
Malta
or
STADA Arzneimittel GmbH
Muthgasse 36/2,
1190 Vienna
Austria
Last review date of this leaflet:November 2021
The detailed information of this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.